The short version of triagonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-11 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Saeujeot (새우젓) or myeolchijeot is not added to the kimchi spice-seasoning mixture, but is simmered first to reduce odors, eliminate tannic flavor and fats, and then is mixed with a thickener made of rice or wheat starch (풀). This technique has been falling into disuse in the past 40 years.
Prior to the introduction of vaccination with material from cases of cowpox (heterotypic immunisation), smallpox could be prevented by deliberate variolation with smallpox virus. According to historian Joseph Needham, Taoists in China as far back as the 10th century practiced a form of inoculation and passed it down through oral tradition, though Needham's claim has been criticized since the practice was not written about. The Chinese also practiced the oldest documented use of variolation, dating back to the fifteenth century. They implemented a method of "nasal insufflation" administered by blowing powdered smallpox material, usually scabs, up the nostrils. Various insufflation techniques have been recorded throughout the sixteenth and seventeenth centuries within China. Two reports on the Chinese practice of inoculation were received by the Royal Society in London in 1700; one by Martin Lister who received a report by an employee of the East India Company stationed in China and another by Clopton Havers. In France, Voltaire reports that the Chinese have practiced variolation "these hundred years".
== Use in specific populations == Hydrocodone can cause neonatal opioid withdrawal syndrome when taken during pregnancy. Reproductive and developmental studies of acetaminophen in rats and mice have shown fetotoxicity, necrosis of the liver and kidney in the pregnant rat and the fetus, retarded growth and decreased reproductive capacity of the offspring. Hydrocodone and acetaminophen are present in breast milk. Chronic opioid use can cause infertility. Safety and efficacy has not been established in patients under the age of 18. Patients over the age of 65 may have heightened sensitivity to hydrocodone. Benzhydrocodone/APAP is mainly excreted through the kidneys; therefore, geriatric patients with impaired renal function may experience more adverse reactions. The effect of renal impairment on the pharmacokinetics of benzhydrocodone/APAP has not been determined. The effect of hepatic impairment on the pharmacokinetics of benzhydrocodone/APAP has not been determined.
Sources: en.wikipedia.org
Clinical Pharmacokinetics is a peer-reviewed medical journal published by Adis International (Springer Nature) that covers topics related to pharmacokinetics. According to the Journal Citation Reports, the journal has a 2024 Impact Factor™ of 4.0 ranked 82 of 352 journals in the Pharmacology & Pharmacy category [Clarivate Analytics]; 2024 CiteScore™ of 7.8 ranked 41 of 275 journals in the Pharmacology [Medical] category [Scopus])
Since there is a relationship between obesity and automobile travel, interventions relating to transportation infrastructure (for example, policy aimed at encouraging the use of public transportation) could potentially reduce obesity.
== Junior career == Zverev played his first junior match in January 2011 at the age of 13 at a grade 4 tournament in Poland. Near the beginning of 2012, Zverev won his first ITF title at the Fujairah Junior Championships, a low-level Grade 4 tournament in the United Arab Emirates. He would pick up a lower level Grade 5 title at the Oman International Junior 2 a few weeks later, which led him to begin competing in higher-level events shortly before his 15th birthday. He did not have much success at tournaments that were Grade 2 and above until the following year when he reached back-to-back doubles finals with Spencer Papa at the Grade A Copa Gerdau and the Grade 1 USTA International Spring Championships. Zverev's early-season success in doubles proved to be the precursor of a major improvement in singles as well. During the European clay court season, he won his first Grade 1 title over Andrey Rublev at the Open International Junior de Beaulieu-sur-Mer. He followed up that performance with his first Grade A title at the Trofeo Bonfiglio a month later, becoming the youngest boys' singles champion in the tournament's history. He also finished runner-up at the 2013 French Open to Cristian Garín. Zverev had some grass court success as well, finishing runner-up to Nick Kyrgios at the Junior International Roehampton. However, he needed to retire at Wimbledon due to a shoulder injury. Zverev came close to reaching another major boys' singles final at the 2013 Junior US Open, but was defeated by the eventual champion Borna Ćorić in the semifinals.
Sources: en.wikipedia.org
It is thought that the symptom of obstruction is caused by the infolding of the circumference of the rectal wall, which "drops down" during defecation and takes up the available space in the anal canal and/or rectum, thereby occluding the lumen. Therefore, the patient may feel like they have feces in their rectum or anal canal, but straining does not relieve the sensation. There is no correlation between the severity of constipation and the degree of internal rectal prolapse as shown on defecography. Furthermore, since a significant amount of people without symptoms have some degree of IRP detectable on defecography, it is debated whether IRP is a cause or effect of obstructed defecation. The fecal incontinence symptom is associated with IRP that has been present for a long time. It has been demonstrated that the severity of internal rectal prolapse, as determined by defecography, has positive correlation with the severity of the fecal incontinence symptom. Fecal incontinence is thought to develop because of occult (undetected) defects of the external anal sphincter, traction induced pudendal neuropathy (nerve damage) caused by stretching of the nerve secondary to chronic straining. The pudendal nerve may undergo irreversible damage if it is stretched by more than 12%. Stretch induced pudendal neuropathy most often results from childbirth (prolonged second stage of labor) and chronic straining (e.g. constipation). There may be widening of the anal canal and reduced sensation. As a result, people with severe IRP may not feel any urge to defecate.
=== Drug and poison discovery === Protein–protein signalling interactions pose suitable therapeutic targets due to their specificity and pervasiveness. The random drug discovery approach uses compound banks that comprise random chemical structures, and requires a high-throughput method to test these structures in their intended target. The cell chosen for the investigation can be specifically engineered to mirror the molecular aspect that the investigator intends to study and then used to identify new human or animal therapeutics or anti-pest agents.
=== Retracted isotopes === In 2003, scientists at the FLNR claimed to have discovered 249No, which would have been the lightest known isotope of nobelium. However, subsequent work showed that the 54 μs fission activity instead originated from an excited state of 250No. The discovery of this isotope was later reported in 2020; its decay properties differed from the 2003 claims.
Copper-free click chemistry is a bioorthogonal reaction as a variant of an azide-alkyne Huisgen cycloaddition. By eliminating cytotoxic copper catalysts, the reaction proceeds without live-cell toxicity. It was developed as a faster alternative to the Staudinger ligation with the first generation of Cu-free click chemistry, producing rate constants over 63 times faster. Although the reaction produces a regioisomeric mixture of triazoles, the lack of regioselectivity in the reaction is not a major concern for its applications in bioorthogonal chemistry. More regiospecific and less bioorthogonal requirements are best served by the traditional Huisgen cycloaddition, especially given the low yield and synthetic difficulty of synthesizing a strained cyclooctyne (compared to the addition of a terminal alkyne). The bioorthogonality of the reaction has allowed the Cu-free click reaction to be applied within cultured cells, live zebrafish, and mice. The absence of exogenous metal catalysts makes the Cu-free chemical reactions suitable for the in vivo applications of bioorthogonal chemistry or bioorthogonal click chemistry.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.